Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / COM
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
21.1M
-
Shares change
-
+3.42M
-
Total reported value, excl. options
-
$538M
-
Value change
-
+$101M
-
Put/Call ratio
-
0.81
-
Number of buys
-
72
-
Number of sells
-
-18
-
Price
-
$25.48
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q2 2020
101 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q2 2020.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.1M shares
.
Largest 10 shareholders include Consonance Capital Management LP (2.84M shares), BAKER BROS. ADVISORS LP (2.8M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (2.44M shares), VANGUARD GROUP INC (1.71M shares), AMERIPRISE FINANCIAL INC (1.49M shares), BlackRock Inc. (1.2M shares), Vivo Capital, LLC (1.15M shares), Sofinnova Investments, Inc. (810K shares), CITADEL ADVISORS LLC (707K shares), and Lion Point Capital, LP (496K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.